Regen BioPharma Inc. is a publicly traded biotechnology company focused on developing innovative treatments using autologous cell therapies, RNA and DNA-based immunotherapy and small molecules in the immune-oncology and autoimmune disease space.
The Company plans to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is advancing therapies for treating cancer and autoimmune disorders by modulating the immune checkpoint NR2F6. The company is also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax, tCellVax, Dura-CAR, KimerApt), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate).
The Company’s primary program is focused on developing modulators of NR2F6, an immune checkpoint for which the Company has a strong patent portfolio. NR2F6 is becoming recognized as a key regulator of T cell function. NR2F6 is anorphan nuclear receptor which naturally suppresses the Nuclear Factor of activated T-cells (“NFAT”) and cytokines that require NFAT for expression including IL-18, IL-17 and IL-2. Regen is currently developing RNA and small molecule drugs that activate or inhibit NR2F6, as well as CAR-T cells genetically modifiedwith NR2F6 blocked. These drugs will be tested for efficacy in various cancersand autoimmune disorders
Regen BioPharma is a biotechnology company focused on stem cell and immunotherapies for speciality niche treatments.
Regen has designed a platform technology that uses aptamers that have dual functionality. Aptamers are DNA or RNA sequences that can bind to and inhibit receptors just like antibodies.
Regen has filed patents on shRNA that is designed to inhibit NR2F6 expression in CAR-T Cells and make these CAR-T cells have long-term, durable effectiveness.
CellVax is a dendritic cell based immunotherapy that stimulates the patient’s immune system through a process called “gene silencing.”
Regen has designed a platform technology that uses aptamers that have dual functionality. Aptamers are DNA or RNA sequences that can bind to and inhibit receptors just like antibodies.
Regen has filed patents on shRNA that is designed to inhibit NR2F6 expression in CAR-T Cells and make these CAR-T cells have long-term, durable effectiveness.
CellVax is a dendritic cell based immunotherapy that stimulates the patient’s immune system through a process called “gene silencing.”
Regen BioPharma is a biotechnology company
focused on stem cell and immunotherapies
for speciality niche treatments.
Regen has designed a platform technology that uses aptamers that have dual functionality. Aptamers are DNA or RNA sequences that can bind to and inhibit receptors just like antibodies.
Regen has filed patents on shRNA that is designed to inhibit NR2F6 expression in CAR-T Cells and make these CAR-T cells have long-term, durable effectiveness.
CellVax is a dendritic cell based immunotherapy that stimulates the patient’s immune system through a process called “gene silencing.”
Regen BioPharma, Inc., is a publicly traded biotechnology company (OTCPINK: RGBP) and (OTCPINK: RGBPP)focused on developing innovative treatments using autologous cell therapies, RNA-and DNA-based immunotherapy and small molecules in the immune-oncology and autoimmunity space.
Regen BioPharma, Inc., is a publicly traded biotechnology company (OTCPINK: RGBP) and (OTCPINK: RGBPP)focused on developing innovative treatments using autologous cell therapies, RNA-and DNA-based immunotherapy and small molecules in the immune-oncology and autoimmunity space.
Regen BioPharma, Inc. invites individual and institutional investors as well as advisors and analysts to
SAN DIEGO, Dec. 19, 2022 /PRNewswire/ — Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP)
Regen BioPharma, Inc. invites individual and institutional investors as well as advisors and analysts, to
SAN DIEGO, Dec. 7, 2022 /PRNewswire/ — Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP)
Regen BioPharma, Inc. invites individual and institutional investors as well as advisors and analysts to attend its real-time, interactive presentation at the Emerging
SAN DIEGO, Dec. 19, 2022 /PRNewswire/ — Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) As 2022 comes to a close, I would
Regen BioPharma, Inc. invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging
SAN DIEGO, Dec. 7, 2022 /PRNewswire/ — Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) announced that Dr. Ravinder Reddy, a Professor of Radiology
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.